DT-7012是针对CCR8的单克隆抗体,旨在增强对固态肿瘤的免疫反应。 Domain Therapeutics starts Phase I/II trial of DT-7012, a monoclonal antibody targeting CCR8 to boost immune response against solid tumors.

在称为DOMISOL的第一阶段/第二阶段试验中,DOMISOL开始对病人施药,测试DT-7012,一种单克隆抗体,其目标为CCR8,以消耗固态肿瘤中的调节T细胞。 Domain Therapeutics has begun dosing patients in a Phase I/II trial called DOMISOL, testing DT-7012, a monoclonal antibody targeting CCR8 to deplete regulatory T cells in solid tumors. 这项开放式,剂量升级研究始于澳大利亚,地点位于墨尔本,旨在评估晚期癌症成年人的安全性,耐受性和早期抗瘤活性. The open-label, dose-escalation study, starting in Australia with sites in Melbourne, aims to assess safety, tolerability, and early anti-tumor activity in adults with advanced cancers. DT-7012是为了加强免疫反应,有选择地针对与肿瘤有关的Tregs,可能克服对目前免疫疗法的抗药性。 DT-7012 is designed to enhance immune response by selectively targeting tumor-associated Tregs, potentially overcoming resistance to current immunotherapies. 这次试验标志着来自域治疗学的第二种专利药物进入临床测试,突出显示了该药物的重点是针对气相化学还原疗法的癌症治疗。 The trial marks the second proprietary drug from Domain Therapeutics to enter clinical testing, highlighting its focus on GPCR-targeted cancer therapies. 预计将很快加入更多的场址。 Additional sites are expected to join soon.